百济神州(6160.HK)跳高25.9% 获全球医药巨头安进27亿美元投资
格隆汇11月1日丨百济神州(6160.HK)跳空高开25.9%,开报105港元,盘前成交65.1万港元,最新总市值824亿港元。中概股百济神州周四发布公告称,与全球医药巨头安进公司建立全球肿瘤战略合作关系。安进将斥资27亿美元,同意为每份百济神州ADS支付174.85美元,较周四收盘价溢价26%,收购百济神州20.5%的股份,以此估算对后者的估值约为135亿美元。按照每百济神州1ADS等于13股普通股,折算成港股这边安进的收购价格为每股105.4港元。据悉,本次合作是中国和美国生物科技领域两家龙头企业的强强联手,是该领域迄今为止金额最大的一次股权投资,也是中国制药公司国际合作史上的最大交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.